Rapid Micro Biosystems, Inc. is a life sciences technology company providing mission-critical automation solutions to facilitate the manufacturing and release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. It offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 49.15% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.59M.
Fairly Valued
The company’s latest PE is -1.54, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 25.08M shares, increasing 2.37% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.